Overview

  • Product nameAnti-TCF7L2 antibody [0.T.149]
    See all TCF7L2 primary antibodies
  • Description
    Mouse monoclonal [0.T.149] to TCF7L2
  • SpecificityRecognizes TCF4 at 66kD in Cos1 cells expressing transfected TCF4
  • Tested applicationsSuitable for: ELISA, IHC-P, ICC/IF, IP, WB, EMSAmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    His-tagged fusion protein, corresponding to amino acids 31-331 of Human TCF4

  • Positive control
    • SW620 whole cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab32873 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
IP Use at an assay dependent concentration.
WB Use a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 66 kDa (predicted molecular weight: 71 kDa).
EMSA Use at an assay dependent concentration.

Target

  • FunctionParticipates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.
  • Tissue specificityDetected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.
  • Involvement in diseaseNote=Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).
    Genetic variations in TCF7L2 are associated with susceptibility to non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
  • Sequence similaritiesBelongs to the TCF/LEF family.
    Contains 1 HMG box DNA-binding domain.
  • Developmental stageHighly expressed in crypt regions and barely detectable in villi in epithelium from fetal small intestine at week 16. At week 22 expression in villi had increased strongly.
  • DomainThe promoter-specific activation domain interacts with the transcriptional coactivator EP300.
  • Post-translational
    modifications
    In vitro, phosphorylated by TNIK.
    Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylated by AXAM/SENP2. Sumoylation/desumoylation regulates TCF4 transcription activity in the Wnt signaling pathway without altering interaction with CTNNB1 nor binding DNA.
  • Cellular localizationNucleus > PML body. Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.
  • Information by UniProt
  • Database links
  • Alternative names
    • HMG box transcription factor 4 antibody
    • hTCF 4 antibody
    • hTCF-4 antibody
    • T cell factor 4 antibody
    • T cell specific HMG box antibody
    • T cell specific transcription factor 4 antibody
    • T-cell factor 4 antibody
    • T-cell-specific transcription factor 4 antibody
    • TCF 4 antibody
    • TCF-4 antibody
    • TCF4 antibody
    • TCF7L2 antibody
    • TCF7L2 protein antibody
    • TF7L2_HUMAN antibody
    • Transcription factor 7 like 2 antibody
    • Transcription factor 7 like 2 T cell specific HMG box antibody
    • Transcription factor 7-like 2 antibody
    see all

Anti-TCF7L2 antibody [0.T.149] images

  • All lanes : Anti-TCF7L2 antibody [0.T.149] (ab32873) at 4 µg/ml

    Lane 1 : Cos-1 cells
    Lane 2 : Cos-1 cells transfected with TCF7L2 cDNA in pUSE


    Predicted band size : 71 kDa
    Observed band size : 60 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 40 kDa. We are unsure as to the identity of these extra bands.

References for Anti-TCF7L2 antibody [0.T.149] (ab32873)

This product has been referenced in:
  • Nagasawa M  et al. Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. Eur J Immunol 38:2389-400 (2008). Read more (PubMed: 18792017) »

See 1 Publication for this product

Product Wall

Application Western blot
Sample Human Cell lysate - nuclear (Jurkat)
Loading amount 60 µg
Specification Jurkat
Gel Running Conditions Reduced Denaturing (10%)
Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Oct 13 2009

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Mouse Cell lysate - whole cell (T lymphocytes, Jurkat)
Loading amount 60 µg
Specification T lymphocytes, Jurkat
Gel Running Conditions Reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Dr. Xiao Qing Lu

Verified customer

Submitted Apr 03 2009

Thank you for your enquiry. Thank you for highlighting these key differences and confusion in the TCF4 nomenclature to me. I have looked into the details of these antibodies and as you highlight ab2233 was raised against TCF4: a bHLH transcription ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"